Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
Sponsor: Epetome
Summary
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks. Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-11
Completion Date
2027-02
Last Updated
2026-11-18
Healthy Volunteers
No
Conditions
Interventions
Synbiotic Dual Cap® Intervention
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.
Locations (1)
Citruslabs
Las Vegas, Nevada, United States